Association between MBOAT7 rs641738 polymorphism and nonalcoholic fatty liver disease

Liao SongLing; Liu ShouSheng; Wang Cong; Chen LiZhen; Xin YongNing; Xuan ShiYing

doi:10.3969/j.issn.1001-5256.2018.10.021

Issue 10

Oct. 2018

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2018 > 34(10): 2169-2174

PDF( 1598 KB)

Association between MBOAT7 rs641738 polymorphism and nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2018.10.021

Dalian Medical University

Research funding:

Published Date: 2018-10-20

Abstract

Abstract

Objective To investigate the association between MOBAT7 rs641738 polymorphism and the development of NAFLD in the Chinese Han population in Qingdao, China, and to provide a theoretical basis for the prevention and treatment of NAFLD and its complication.Methods A total of 113 NAFLD patients who were treated in Qingdao Municipal Hospital and 74 healthy controls were enrolled in this study. Blood samples were collected, DNA was extracted, and PCR and time-of-flight mass spectrometry were used to determine the genotype of MBOAT7 rs641738. The chi-square test was used to determine whether the distribution of genotypes met the Hardy-Weinberg equilibrium, in order to assess the group representativeness of samples. Clinical data and biochemical results including liver function were collected.The chi-square test was used for comparison of sex and genotype and allele frequencies between the two groups. The independent samples t-test and Wilcoxon rank sum test were used for comparison of continuous data between the two groups. The relative risk of NAFLD associated with gene polymorphisms was expressed as odds ratio ( OR) and 95% confidence interval ( CI) , and the non-conditional logistic regression model was used to calculate OR and 95% CI. Results There was no significant difference in the distribution of CC, CT, and TT genotypes of MBOAT7 rs641738 between the NAFLD group and the control group ( χ2= 0. 157, P = 0. 692) , and there was also no significant difference in the distribution of C and T alleles between the two groups ( χ2= 0. 365, P = 0. 546) . The non-conditional logistic regression analysis showed that the carriers with CC + CT genotypes of MBOAT7 rs641738 had a similar risk of NAFLD as those with CC genotype ( OR = 0. 923, 95% CI: 0. 685-1. 245, P = 0. 692) ; there was also no significant difference after adjustment for sex, age, and body mass index ( corrected OR = 0. 893, 95% CI: 0. 652-1. 223, P = 0. 481) . In the NAFLD group, the carriers with CC + CT genotypes had significantly lower levels of total cholesterol and low-density lipoprotein than those with CC genotype ( t =-2. 348 and-2. 113, P = 0. 021 and0. 037) , and there were no significant differences in the other indices ( all P > 0. 05) . Conclusion There is no significant association between MBOAT7 rs641738 polymorphism and the risk of NAFLD in the Chinese Han population in Qingdao.
- non-alcoholic fatty liver disease,
- polymorphism, single nucleotide,
- MBOAT7

FullText(HTML)

References(19)

References

[1]COHEN JC, HORTON JD, HOBBS HH.Human fatty liver disease:Old questions and new insights[J].Science, 2011, 332 (6037) :1519-1523.

[2]LI SP, WANG QC.Progress of the epidemiology of non-alcoholic fatty liver disease[J].Chin J Gastroenterol Hepatol, 2017, 26 (10) :1085-1087. (in Chinese) 李生鹏, 王全楚.非酒精性脂肪性肝病的流行病学进展[J].胃肠病学和肝病学杂志, 2017, 26 (10) :1085-1087.

[3]SEVERSON TJ, BESUR S, BONKOVSKY HL.Genetic factors that affect nonalcoholic fatty liver disease:A systematic clinical review[J].World J Gastroenterol, 2016, 22 (29) :6742-6756.

[4]DONGIOVANNI P, VALENTI L.Genetics of nonalcoholic fatty liver disease[J].Metabolism, 2016, 65 (8) :1026-1037.

[5]HU ZJ, ZHANG J.Current status of research on nonalcoholic fatty liver disease in China[J].J Clin Hepatol, 2016, 32 (3) :552-555. (in Chinese) 胡中杰, 张晶.我国非酒精性脂肪性肝病的研究现状[J].临床肝胆病杂志, 2016, 32 (3) :552-555.

[6]GIJON MA, RIEKHOF WR, ZARINI S, et al.Lysophospholipid acyltransferases and arachidonate recycling in human neutrophils[J].J Biol Chem, 2008, 283 (44) :30235-30245.

[7]LEE HC, INOUE T, IMAE R, et al.Caenorhabditis elegans mboa-7, a member of the MBOAT family, is required for selective incorporation of polyunsaturated fatty acids into phosphatidylinositol[J].Mol Biol Cell, 2008, 19 (3) :1174-1184.

[8]DAUWERSE JG, de VRIES BB, WOUTERS CH, et al.At (4;6) (q12;p23) translocation disrupts a membrane-associated O-acetyl transferase gene (MBOAT1) in a patient with a novel brachydactyly-syndactyly syndrome[J].Eur J Hum Genet, 2007, 15 (7) :743-751.

[9]PEREZ-CHACON G, ASTUDILLO AM, BALGOMA D, et al.Control of free arachidonic acid levels by phospholipases A2 and lysophospholipid acyltransferases[J].Biochim Biophys Acta, 2009, 1791 (12) :1103-1113.

[10]LANDS WE.Metabolism of glycerolipides;a comparison of lecithin and triglyceride synthesis[J].J Biol Chem, 1958, 231 (2) :883-888.

[11]ZARINI S, HANKIN JA, MURPHY RC, et al.Lysophospholipid acyltransferases and eicosanoid biosynthesis in zebrafish myeloid cells[J].Prostaglandins Other Lipid Mediat, 2014, 113-115:52-61.

[12]KRAWCZYK M, RAU M, SCHATTENBERG JM, et al.Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity:A multicenter biopsy-based study[J].J Lipid Res, 2017, 58 (1) :247-255.

[13]MANCINA RM, DONGIOVANNI P, PETTA S, et al.The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of european descent[J].Gastroenterology, 2016, 150 (5) :1219-1230.

[14]THABET K, ASIMAKOPOULOS A, SHOJAEI M, et al.MBOAT7rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C[J].Nat Commun, 2016, 7:12757.

[15]LIN YC, CHANG PF, CHANG MH, et al.Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children[J].Liver Int, 2018, 38 (7) :1300-1307.

[16]Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association.Guidelines for management of non-alcoholic fatty liver disease[J].J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志, 2010, 26 (2) :120-124.

[17]BUCH S, STICKEL F, TREPO E, et al.A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7as risk loci for alcohol-related cirrhosis[J].Nat Genet, 2015, 47 (12) :1443-1448.

[18]LUUKKONEN PK, ZHOU Y, HYOTYLAINEN T, et al.The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans[J].J Hepatol, 2016, 65 (6) :1263-1265.

[19]DONATI B, DONGIOVANNI P, ROMEO S, et al.MBOAT7rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals[J].Sci Rep, 2017, 7 (1) :4492.

Relative Articles

[1]	Long HAI, Lina MA, Xia LUO, Xiangchun DING. Effect of miRNA-933 on the apoptosis and proliferation of LX-2 cells and its molecular mechanism[J]. Journal of Clinical Hepatology, 2024, 40(7): 1382-1389. doi: 10.12449/JCH240716
[2]	Yao ZHANG, Kai ZHANG, Pengdong KANG, Chao MA. Research advances in microRNA-200c in pancreatic cancer[J]. Journal of Clinical Hepatology, 2022, 38(4): 961-964. doi: 10.3969/j.issn.1001-5256.2022.04.045
[3]	Sheng CHEN, Guoxiang CHEN, Zhongming HE, Shujie CHENG, Jisen ZHAO. Role of miRNA in the development and progression of cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2021, 37(9): 2241-2245. doi: 10.3969/j.issn.1001-5256.2021.09.048
[4]	Huijun XIE, Nasot Rashed, Yong NING, Chuan GAO. Current status of research on circulating microRNAs as diagnostic markers for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(2): 448-451. doi: 10.3969/j.issn.1001-5256.2021.02.042
[5]	Xuemei DING, Shilun WU, Wenbing SUN. Value of preoperative microRNA-192 in peripheral blood mononuclear cells in predicting microvascular invasion of solitary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1121-1125. doi: 10.3969/j.issn.1001-5256.2021.05.028
[6]	Xiuhong HUANG, Xiaoli XIE, Huiqing JIANG. Value of a microRNA risk score model in predicting the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1110-1115. doi: 10.3969/j.issn.1001-5256.2021.05.026
[7]	Wu Jie, Li JingTao, Wei HaiLiang, Yan ShuGuang, Fan Yu, Guo YingJun, Chang ZhanJie. Advances in the role of microRNA in the intervention of malignant transformation of precancerous lesions of the liver by regulating the activation of hepatic stellate cells[J]. Journal of Clinical Hepatology, 2020, 36(7): 1650-1654. doi: 10.3969/j.issn.1001-5256.2020.07.045
[8]	Guo Xuan, Tan Wei, Wang ChangJun. Mechanism of action of circular RNAs in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(10): 2340-2343. doi: 10.3969/j.issn.1001-5256.2020.10.039
[9]	Cheng YaFei, Wang Bin, Wang ShiMing. Role of microRNAs in gallbladder carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(8): 1900-1904. doi: 10.3969/j.issn.1001-5256.2020.08.049
[10]	Wang ZeXin, Guan LiJun, Li JianMing, Wang ZhiChao, Xue MengRuo, Qin XiaoJun. Effect of targeted regulation of the Wnt2 gene by microRNA( microRNA-21) on the proliferation and migration of HepG2 hepatoma cells[J]. Journal of Clinical Hepatology, 2020, 36(4): 803-807. doi: 10.3969/j.issn.1001-5256.2020.04.019
[11]	Wu JunYi, Lai ZhiDe, Tian YiFeng, Wang YaoDong. Expression and clinical significance of serum exosomal microRNA-221-3p in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(8): 1768-1772. doi: 10.3969/j.issn.1001-5256.2020.08.018
[12]	Huang XiangJun, Zhang WenXing. Expression features and clinical significance of the microRNA-888 gene family in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(1): 119-122. doi: 10.3969/j.issn.1001-5256.2019.01.022
[13]	Niu YaQian, Chang YuLing, Liu Fang, Zhao Chuan, Chen Che. Regulatory role of microRNA in aerobic glycolysis in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(9): 2082-2084. doi: 10.3969/j.issn.1001-5256.2019.09.044
[14]	Zhang ZhuQing, Lu ShuMing, Wang HuaLi, Xu MengYao, Li ChunYan, Xin Yue, Zhao JunJun. Expression of microRNA-222 in hepatocellular carcinoma tissue and its clinical significance[J]. Journal of Clinical Hepatology, 2017, 33(8): 1502-1505. doi: 10.3969/j.issn.1001-5256.2017.08.018
[15]	Wang DongXu, Huo TingTing, Tian YaoWen, Zhao Lei. Current status of research on microRNA associated with colorectal cancer liver metastasis[J]. Journal of Clinical Hepatology, 2016, 32(12): 2387-2390. doi: 10.3969/j.issn.1001-5256.2016.12.034
[16]	Qiu Hua, Sun XueHua, Zhou ZhenHua, Li Man, Zhang Xin, Gao YueQiu. Influence of interaction between endogenous miRNAs and hepatitis B virus in hepatocytes on hepatitis B virus transcription and related mechanisms[J]. Journal of Clinical Hepatology, 2016, 32(11): 2186-2190. doi: 10.3969/j.issn.1001-5256.2016.11.042
[17]	Xiao ZuoHan, Meng Gang, Wang LiZhi, Sun WenJin. Diagnostic value of combined determination of DNA ploidy level and miRNA-21 expression in ascites cells for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(1): 93-98. doi: 10.3969/j.issn.1001-5256.2015.01.020
[18]	Li Qiang, Zhuo QiBin, Huang YuXian, Chen Liang. Diagnosis and treatment of hepatocellular carcinoma from a new perspective of miRNAs[J]. Journal of Clinical Hepatology, 2015, 31(6): 977-981. doi: 10.3969/j.issn.1001-5256.2015.06.037
[19]	Qu YaChao, LYU Jun. Research progress in serum microRNA detection for diagnosis of hepatocellular carcinoma [J]. Journal of Clinical Hepatology, 2014, 30(3): 228-232. doi: 10.3969/j.issn.1001-5256.2014.03.008
[20]	Guo JinSheng. Recent perspectives on mechanisms of liver fibrogenesis: microRNA and cell autophagy [J]. Journal of Clinical Hepatology, 2013, 29(5): 324-326.

Supplements(0)

Cited By

Cited by

Periodical cited type(1)

孙巍，丁晓燕，陈京龙，李文东，郭晓笛，申燕军，滕颖，刘晓民，魏建莹. MicroRNA-520a通过失活AKT抑制HepG2.2.15细胞中HBV DNA复制. 中国肝脏病杂志(电子版). 2018(04): 73-78 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2682) PDF downloads(399)

Association between MBOAT7 rs641738 polymorphism and nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2018.10.021